United States Influenza Vaccines Market Report, Analysis and Forecast to 2025
SKU ID :DPI-12434341 | Published Date: 16-Oct-2018 | No. of pages: 130Description
TOC
1. Executive Summary
2. United States Influenza Vaccines Market Size & Analysis (2013 - 2025)
3. United States Number of Persons Vaccinated with Influenza Vaccines (2013 - 2025)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Inhibitors
5. United States Influenza Vaccines Pricing Trends & Analysis
6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
7. United States Influenza Vaccines Distribution & Demand (2010 - 2018)
8. Effectiveness of Influenza Vaccines in United States (2004 – 2018)
9. Rapid Diagnostic Testing for the Management of Influenza
10. Distribution Channel & Technique of Influenza Vaccination in United States
11. United States Influenza Vaccines Reimbursement Policies & Regulatory System
11.1 Reimbursement Policies
11.2 Regulation System
12. Major Deals in United States Influenza Vaccines Market
12.1 Merger & Acquisitions
12.2 Collaboration Deal
12.3 Licensing Agreement
12.4 Exclusive Agreement
12.5 Distribution Agreement
13. Promising Influenza Vaccines in Clinical Development
14. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
14.1 Year 2018
14.2 Year 2017
15. Key Companies Analysis
15.1 Sanofi Pasteur
15.1.1 Business Overview
15.1.2 Influenza Vaccines Portfolio
15.1.3 Influenza Vaccine Value Sales Analysis
15.1.4 Recent Development
15.2 GlaxoSmithKline (GSK)
15.2.1 Business Overview
15.2.2 Influenza Vaccines Portfolio
15.2.3 Influenza Vaccine Sales Value Analysis
15.2.4 Recent Development
15.3 Seqirus
15.3.1 Business Overview
15.3.2 Influenza Vaccines Portfolios
15.3.3 Recent Development
15.4 AstraZeneca
15.4.1 Business Overview
15.4.2 Influenza Vaccines Portfolio
15.4.3 Influenza Vaccine Sales Value Analysis
15.4.4 Recent Development
Tables & Figures
Table 4–1: BiondVax Pharmaceuticals Ltd. Clinical Trials
Table 5–1: United States Pediatric Influenza Vaccines Price, 2018 – 2019
Table 5–2: United States Adult Influenza Vaccine Price, 2018 – 2019
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–2: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2018
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 11–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 12–1: Merger & Acquisitions in Influenza Vaccines Market (Million US$),2003 – 2017
Table 12–2: Collaboration Deal in Influenza Vaccines Market,2007 – 2018
Table 12–3: Licensing Agreement in Influenza Vaccines Market,2007 – 2018
Table 12–4: Exclusive Agreement in Influenza Vaccines Market,2009 – 2016
Table 12–5: Distribution Agreement in Influenza Vaccines Market,2005 – 2016
Figure 2–1: United States Influenza Vaccines Market (Million US$),2013 – 2017
Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2018 – 2025
Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2017
Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2018 – 2025
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2013 – 2017
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2018 – 2025
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2013 – 2017
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2018 – 2025
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2018
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults,2017 - 2018
Figure 15–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2017
Figure 15–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2018 – 2025
Figure 15–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2017
Figure 15–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2018 – 2025
Figure 10–5: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2011 – 2015
Companies
Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca
- PRICE
-
$1390$2090